Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer

Sponsor
Hebei Medical University Fourth Hospital
Study ID
NCT06184698
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a multi-center, single-arm study to investigate the efficacy and safety of liposomal irinotecan+5-FU/LV+ bevacizumab as second-line therapy in metastatic colorectal cancer in Chinese population.

Key Dates

Start date
Jan 1, 2024
Status verified
Sep 2024
Primary completion
Feb 1, 2026
Completion
Mar 1, 2027

Study Design

Enrollment
173 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental Group
    liposomal irinotecan+5-FU/LV+ bevacizumab q2w

Primary Outcome Measure

Objective Response Rate [ Time Frame: 4 months ]

Central Contacts

Related Studies